Literature DB >> 22527088

What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?

Andrea Billè1, Lawrence Okiror, Wolfram Karenovics, John Pilling, Loïc Lang-Lazdunski.   

Abstract

Malignant pleural mesothelioma (MPM) increases the risk of venous thromboembolic (VTE) events. This risk is higher following extrapleural pneumonectomy (EPP) as part of trimodality therapy, where VTE can be catastrophic. In our series, the impact of warfarin in preventing a pulmonary embolus (PE) after neoadjuvant chemotherapy and EPP for MPM was analysed. A retrospective analysis of 21 consecutive patients undergoing EPP for MPM was conducted. The first 10 patients (Group A) had VTE prophylaxis by subcutaneous enoxaparin and compression stockings commenced a day prior to surgery, intraoperative pneumatic calf compression and early post-operative mobilization. Enoxaparin was continued for 30 days postoperatively. The following 11 patients (Group B) had the same VTE prophylaxis, together with warfarin, started prior to hospital discharge and continued for 6 months postoperatively. All patients had a computed tomography pulmonary angiogram within 8 weeks after surgery and a full examination at 1, 3, 6 and 12 months. Both groups were comparable for characteristics. Three patients in Group A suffered a PE at 4, 6 and 16 weeks postoperatively. One PE was fatal. No patient in Group B suffered VTE (P = 0.05, χ(2) test) or haemorrhagic complications. Warfarin anticoagulation following EPP is feasible and safe, and is associated with a significant reduction in VTE complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527088      PMCID: PMC3397743          DOI: 10.1093/icvts/ivs158

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  15 in total

1.  Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.

Authors:  R J Hettiarachchi; S M Smorenburg; J Ginsberg; M Levine; M H Prins; H R Büller
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits.

Authors:  Christophe Doddoli; Fabrice Barlesi; Delphine Trousse; Stéphane Robitail; Sadio Yena; Philippe Astoul; Roger Giudicelli; Pierre Fuentes; Pascal Thomas
Journal:  J Thorac Cardiovasc Surg       Date:  2005-08       Impact factor: 5.209

3.  Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

Authors:  P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

4.  Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.

Authors:  Apurva Patel; Masaki Anraku; Gail E Darling; Frances A Shepherd; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee; Marc de Perrot
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-10       Impact factor: 5.209

5.  Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer.

Authors:  Walter Weder; Stéphane Collaud; Wilfried E E Eberhardt; Sven Hillinger; Stefan Welter; Rolf Stahel; Georgios Stamatis
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-24       Impact factor: 5.209

6.  Rate of thromboembolic events in mesothelioma.

Authors:  Derrick Nguyen; Sang-Joon Lee; Edward Libby; Claire Verschraegen
Journal:  Ann Thorac Surg       Date:  2008-03       Impact factor: 4.330

7.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

8.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

9.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

10.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

View more
  2 in total

1.  Technical pitfalls and solutions in extrapleural pneumonectomy.

Authors:  Stephane Collaud; Marc de Perrot
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 2.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.